As the threat of antibacterial resistance rises, new antibiotics are sorely needed as microbes mutate and get better at outsmarting current therapies available for bacterial infections.
Academic research institutions play a crucial role in the drug development process, especially on the preclinical research and drug discovery side, as Big Pharma companies are increasingly cutting back their R&D spending. While many of the research institutions featured here are still doing plenty of basic science research, interest seems to be growing among these universities in repurposing existing drugs or those that never made it into the marketplace because of safety issues.
We've taken a look at some of the best research institutions in the U.S. and ranked by them by their level of funding from the National Institutes of Health, the largest funder of biomedical research in the world. The report highlights some of the important drug discovery research coming out of these universities that FierceBiotech Research covered in 2013, but it is by no means a comprehensive look at every research initiative at these institutions.
FierceBiotech is now available on iPhone and iPad!
This is the best FierceBiotech reading experience we've ever created. Swipe right-to-left within articles to quickly scan the latest news. Get breaking news alerts sent to your mobile device so you're the first to know when a major story unfolds. Download it today; the app is an essential complement to our e-mail newsletter and website.
Android users: We're on track to have an app complete by the end of the year.
Have something to say? Join the conversation at
FierceBiotech's LinkedIn group.
POPULAR COMMENT THREADS
International Stem Cell Corp. is inching closer to bringing its stem cell therapy for Parkinson's to the FDA in hopes of eventually reversing the disease's symptoms in people.
Announced earlier this week, President Barack Obama's proposed budget for 2015 includes $30.4 billion for the National Institutes of Health, a slight increase of $211 million over this fiscal year's budget.
The National Institute of Allergy and Infectious Diseases has awarded a 7-year, $9.8 million grant to develop an AIDS vaccine to four Seattle-based research organizations and Rockefeller University.
A class of FDA-approved antipsychotic drugs may provide a new approach to treating the most aggressive form of primary brain cancer, glioblastoma.
Oregon Health & Science University is opening a new Center for Embryonic Cell and Gene Therapy to study experimental treatments for Parkinson's disease, multiple sclerosis and a range of other conditions caused by diseased or injured cells in the human body.
Researchers think they've discovered why previous efforts at targeting the enzyme LTA4 hydrolase, a key player in the body's inflammatory response, have failed and produced a new molecule that may prove more successful.
From Our Sister Sites
North Carolina's Clinipace is looking to scale up its global presence, buying out Hong Kong CRO Choice Pharma and planning to merge its operations into a transcontinental player.
AngioDynamics said it won expanded FDA clearance for one of its key vascular access devices, a development that could help it boost the market reach for a product it bills as a healthcare cost-cutter.